retatrutide clinical trial results retatrutide weight loss Safety, Side Effects & Provider Use Retatrutide vs Tirzepatide: Which Peptide

Mol Metab 32, 4455 (2020)

The drug development partners had been seeking approval for patritumab deruxtecan, an antibody-drug conjugate (ADC), to treat patients with advanced or metastatic NSCLC bearing certain genetic mutations

Lancet (2021) 397(10284):157790

In the SURMOUNT-2 trial [2] involving patients with type 2 diabetes, the weight loss was 14.7% at the highest dose

The advent of glucagon-like peptide-1 receptor agonists (GLP-1RA) has transformed diabetes care, not only through improvements in HbA1c and body weight, but by demonstrating a consistent reduction in major adverse cardiovascular events (MACE)

Im so happy, satisfied and delighted with the result